Anixa Biosciences (NASDAQ:ANIX) Stock Rating Upgraded by Wall Street Zen

Anixa Biosciences (NASDAQ:ANIX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Monday.

ANIX has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a report on Monday, December 29th. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, February 4th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.50.

Anixa Biosciences Trading Down 4.3%

Shares of Anixa Biosciences stock opened at $2.65 on Monday. Anixa Biosciences has a 1 year low of $2.33 and a 1 year high of $5.46. The company’s fifty day simple moving average is $2.98 and its 200-day simple moving average is $3.54. The company has a market cap of $88.85 million, a price-to-earnings ratio of -8.03 and a beta of 0.48.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Monday, March 9th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. As a group, research analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Arnold M. Baskies bought 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Wednesday, January 28th. The stock was purchased at an average cost of $3.04 per share, with a total value of $30,400.00. Following the completion of the transaction, the director directly owned 135,000 shares in the company, valued at $410,400. This trade represents a 8.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 26.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. boosted its position in shares of Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after acquiring an additional 10,000 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Anixa Biosciences in the fourth quarter worth about $83,000. Geode Capital Management LLC lifted its stake in Anixa Biosciences by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after purchasing an additional 7,271 shares during the period. Bank of America Corp DE lifted its stake in Anixa Biosciences by 1.7% during the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock worth $706,000 after purchasing an additional 3,645 shares during the period. Finally, Susquehanna International Group LLP boosted its holdings in Anixa Biosciences by 378.4% during the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock valued at $265,000 after purchasing an additional 63,584 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.